Literature DB >> 9776732

Regulation of angiopoietin-2 mRNA levels in bovine microvascular endothelial cells by cytokines and hypoxia.

S J Mandriota1, M S Pepper.   

Abstract

Angiopoietin-2 (Ang2) is a ligand for the endothelial cell tyrosine kinase receptor Tie2 and counteracts blood vessel maturation/stability mediated by angiopoietin-1 (Ang1), the other known ligand of Tie2. Using degenerate oligonucleotides and reverse transcriptase-polymerase chain reaction, we have screened bovine microvascular endothelial (BME), aortic, lymphatic, pulmonary artery, and transformed fetal aortic endothelial cells, as well as rat smooth muscle cells for Ang1 and Ang2 expression. Except for high Ang2 mRNA levels found in BME cells, none of the endothelial cell types studied expressed appreciable levels of Ang1 or Ang2 mRNAs, whereas smooth muscle cells expressed both Ang1 and Ang2. BME cell Ang2 mRNA levels were increased by vascular endothelial growth factor (1.9- to 2.9-fold), basic fibroblast growth factor (1.6- to 2-fold), both cytokines in combination (2.9- to 4-fold), and hypoxia (3.1- to 5.6-fold) and were decreased by Ang1 (31% to 70%) or transforming growth factor-ss1 (64% to 81%). Ang2 also decreased (60% to 82%) BME cell Ang2 mRNA. mRNA levels for the Tie1 or Tie2 receptors were only slightly modulated under the conditions described above. These findings suggest that the angiogenic effect of a number of regulators may be achieved in part through the regulation of an autocrine loop of Ang2 activity in microvascular endothelial cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9776732     DOI: 10.1161/01.res.83.8.852

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  79 in total

Review 1.  Vascular growth factors in cerebral ischemia.

Authors:  S D Croll; S J Wiegand
Journal:  Mol Neurobiol       Date:  2001 Apr-Jun       Impact factor: 5.590

Review 2.  Surviving ischemia: adaptive responses mediated by hypoxia-inducible factor 1.

Authors:  G L Semenza
Journal:  J Clin Invest       Date:  2000-10       Impact factor: 14.808

Review 3.  Causes and effects of heterogeneous perfusion in tumors.

Authors:  R J Gillies; P A Schornack; T W Secomb; N Raghunand
Journal:  Neoplasia       Date:  1999-08       Impact factor: 5.715

Review 4.  Soluble flt-1 and the angiopoietins in the development and regulation of placental vasculature.

Authors:  D Stephen Charnock-Jones
Journal:  J Anat       Date:  2002-06       Impact factor: 2.610

Review 5.  Myoblast-mediated gene transfer for therapeutic angiogenesis and arteriogenesis.

Authors:  Georges von Degenfeld; Andrea Banfi; Matthew L Springer; Helen M Blau
Journal:  Br J Pharmacol       Date:  2003-10       Impact factor: 8.739

6.  Generation and characterization of telomerase-transfected human lymphatic endothelial cells with an extended life span.

Authors:  Riccardo E Nisato; Jillian A Harrison; Raphaele Buser; Lelio Orci; Chris Rinsch; Roberto Montesano; Philippe Dupraz; Michael S Pepper
Journal:  Am J Pathol       Date:  2004-07       Impact factor: 4.307

Review 7.  Mathematical modeling of tumor-induced angiogenesis.

Authors:  Nikos V Mantzaris; Steve Webb; Hans G Othmer
Journal:  J Math Biol       Date:  2004-02-06       Impact factor: 2.259

8.  A versatile valve-enabled microfluidic cell co-culture platform and demonstration of its applications to neurobiology and cancer biology.

Authors:  Yandong Gao; Devi Majumdar; Bojana Jovanovic; Candice Shaifer; P Charles Lin; Andries Zijlstra; Donna J Webb; Deyu Li
Journal:  Biomed Microdevices       Date:  2011-06       Impact factor: 2.838

Review 9.  Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma.

Authors:  Shinji Tanaka; Shigeki Arii
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.402

Review 10.  Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system.

Authors:  Hellmut G Augustin; Gou Young Koh; Gavin Thurston; Kari Alitalo
Journal:  Nat Rev Mol Cell Biol       Date:  2009-03       Impact factor: 94.444

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.